Pathology Laboratories, Inc., commonly referred to as Pathology Labs, is a leading provider of diagnostic services headquartered in the United States. Established in 1995, the company has grown to serve major operational regions across the country, specialising in an array of pathology services that cater to healthcare providers and patients alike. With a focus on histopathology, cytopathology, and molecular diagnostics, Pathology Labs distinguishes itself through its commitment to accuracy and rapid turnaround times. The company has achieved notable milestones, including the implementation of advanced technologies that enhance diagnostic precision. Recognised for its exceptional quality and reliability, Pathology Laboratories, Inc. continues to solidify its position as a trusted partner in the healthcare industry, contributing significantly to patient care and clinical outcomes.
How does Pathology Laboratories, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pathology Laboratories, Inc.'s score of 66 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pathology Laboratories, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Sonic Healthcare Limited, which may influence its climate commitments and reporting practices. As of now, there are no documented reduction targets or climate pledges from Pathology Laboratories, Inc. However, emissions data and performance metrics may be inherited from its parent company, Sonic Healthcare Limited, at a cascade level of 2. This means that any climate initiatives or emissions reductions reported by Sonic Healthcare could potentially reflect on Pathology Laboratories, although specific figures or commitments are not detailed. In the broader context, the healthcare sector is increasingly focusing on sustainability and reducing carbon footprints, which may guide Pathology Laboratories, Inc. in future climate strategies. Without specific data or commitments, the company's current stance on carbon emissions remains unclear.
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 8,124,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 
| Scope 2 | 59,156,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
Pathology Laboratories, Inc.'s Scope 3 emissions, which increased by 13% last year and increased by approximately 1% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 43% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pathology Laboratories, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.